Some new aspects of the effect of (−)deprenyl in Parkinson's disease—a retrospective study
Author:
- 1 June 1992
- journal article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 4 (2) , 155-164
Abstract
50 de novo patients with Parkinson's disease were investigated in a retrospective study after selegiline (−)deprenyl monotherapy and a combination of (−)deprenyl and levodopa. The study involved subjects with different Hoehn-Yahr stages (I, II, III, IV). During the treatment period the distribution of age (below 60 yr or above 60 yr) among the Hoehn-Yahr stages was similar to that of the baseline period, while the clinical disability for the patients starting with hypokinesis meant a more severe state compared to the cases with tremor. The sex ratio was similar during the baseline period but later, during the administration of deprenyl, the progression of males was slower than that of females. (−)Deprenyl was effective in decreasing the hypokinesis, while the rigidity was improved less by this drug. The reduction of parkinsonian symptoms developed slowly and was independent of the severity of Parkinson's disease. The maintenance of deprenyl monotherapy showed a high individual variation but the average period was about one year. The termination fo the effect of deprenyl was rapid, however, not progressive. The time of the appearance of the side effects of additional levodopa was not delayed by deprenyl treatment. After five years the severity of disease was similar to the baseline disability scores in spite of the combined therapy with levopoda and deprenyl.Keywords
This publication has 24 references indexed in Scilit:
- Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's diseaseBrain Research, 1990
- L-Deprenyl, Levodopa Pharmacokinetics, and Response Fluctuations in Parkinsonʼs DiseaseClinical Neuropharmacology, 1990
- Selegiline as an Adjunct to Conventional Levodopa Therapy in Parkinson's DiseaseArchives of Neurology, 1989
- Effect of Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1989
- Histochemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson’s disease?1989
- Release of endogenous dopamine from rat isolated striatum: effect of clorgyline and (−)−deprenylBritish Journal of Pharmacology, 1984
- Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeysEuropean Journal of Pharmacology, 1984
- Dopaminergic Neurotoxicity of 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine in MiceScience, 1984
- Deprenyl (selegiline): the history of its development and pharmacological actionActa Neurologica Scandinavica, 1983
- Deprenyl (selegiline) in the treatment of Parkinson's diseaseActa Neurologica Scandinavica, 1983